The new strategies had been thoroughly reviewed in 2021 and 2022 but depend seriously on country and region-specific dynamic products for very low and middle-income nations around the world that experienced important COVID-linked disruptions to TB diagnosis and procedure, while in the absence of trusted direct measurements of sickness load https://hc6.org/